SSG
KYMR icon

Summit Securities Group’s Kymera Therapeutics KYMR Stock Holding History

Summit Securities Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Buy
+750
New +$64.4K 0.01% 458
2025
Q2 		– Sell
-140
Closed -$3.83K – 1262
2025
Q1 		$3.83K Buy
+140
New +$5.1K ﹤0.01% 629

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Summit Securities Group's KYMR Position: Q2 2026 in Review

Summit Securities Group opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 750 shares worth $86K. The stake represents 0.01% of the portfolio and ranks #458 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in KYMR as recently as Q1 2025.

Summit Securities Group first reported a position in KYMR in Q1 2025 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Summit Securities Group held 750 shares of Kymera Therapeutics worth $86K as of Q2 2026.
  • Kymera Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Kymera Therapeutics made up 0.01% of Summit Securities Group's portfolio in Q2 2026, its #458 holding.
  • Summit Securities Group first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.